





Addressing unmet needs in metastatic breast cancer (MBC)

ER+/HER2- MBC today and tomorrow

The last **10 years** have seen a **lack of improvement** in clinical outcomes for first-line estrogen-receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) MBC¹



Median **survival** following MBC diagnosis



is currently **2–4 years**²

Only

1 in **5** MBC patients survives to **5 years**^{3,4}



Options are needed to improve **progression-free survival (PFS)** with first-line therapy for ER+/HER2- MBC



New agents and combinations have the potential to transform outcomes, improving

disease control while maintaining patient **quality of life**¹

